AtaiBeckley Inc. (ATAI) Gains Momentum With Promising BPL-003 Data and Strong Analyst Support

Finviz2026/02/13 12:15

By:Finviz

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

AtaiBeckley Inc. (NASDAQ:ATAI) is one of Goldman Sachs’ top penny stock picks. On January 16 at the 64th Annual Meeting of the American College of Neuropsychopharmacology (ACNP), AtaiBeckley Inc. (NASDAQ:ATAI) delivered promising clinical data on BPL-003 for treatment-resistant depression.

AtaiBeckley Inc. (ATAI) Gains Momentum With Promising BPL-003 Data and Strong Analyst Support image 0

Source:pixabay

The results affirmed the development of transformative mental health therapies. The Phase 2b study for BPL-003 affirmed significant and sustained antidepressant effects in the treatment of resistant depression. The results assert potential commercial viability. AtaiBeckley has already secured Breakthrough Therapy designation for BPL-003 from the Food and Drug Administration.

Dr Kevin Craig, Chief Medical Officer at AtaiBeckley, said, “We are delighted that our Phase 2b BPL-003 results were not only selected for poster presentation but also recognized as a Hot Topic, one of the most competitive and prestigious categories at ACNP. This distinction underscores the strength and impact of our clinical findings in treatment-resistant depression.

On January 20, Guggenheim initiated coverage of AtaiBeckley with a Buy rating and an $11 price target, calling it a standout in next-generation psychiatry. The firm said the merger with Beckley Psytech secures full ownership of its lead drug, BPL-003, which has delivered strong and lasting results in Phase IIb trials for treatment-resistant depression, positioning it well for broad clinical use and commercial growth.

Earlier, on January 13, analysts at Cantor Fitzgerald reiterated an Overweight rating on AtaiBeckley. The research firm remains optimistic that the candidate drug BPL-003 will become one of the key players in the psychedelic treatment landscape.

AtaiBeckley Inc. (NASDAQ:ATAI) is a clinical-stage biopharmaceutical company focused on developing innovative psychedelic-based and neuroplasticity-promoting treatments for mental health disorders, such as treatment-resistant depression and social anxiety.

While we acknowledge the potential of ATAI as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 12 Best Long-Term Stocks to Invest in for Retirement and 10 High-Growth Cybersecurity Stocks To Buy.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

1. U.S. equities gained over the week, while crypto assets declined, reflecting a divergence in risk appetite. From October 3 to 9, the S&P 500 rose 1.15% and the Nasdaq 100 gained 0.24%, while BTC, ETH, and SOL fell 2.31%, 6.84%, and 7.99%, respectively. The U.S. Dollar Index advanced 0.27%, and although the 10-year U.S. Treasury yield declined 3.3 basis points, it remained elevated at 5.244%. High funding costs therefore continued to weigh on risk asset valuations. 2. Weak employment data have not eliminated inflation concerns, while AI and on-chain finance face growing scrutiny over commercial viability. September nonfarm payrolls increased by just 29,000, yet the minutes of the Federal Reserve's September meeting still pointed to the possibility of further rate hikes before year-end. This week's CPI release and major bank earnings will provide important tests of growth and inflation pressures. Revenue recognition and reporting practices in AI, underlying asset rights in RWA, and operating costs for Layer 2 networks are also becoming increasingly important measures of commercial viability. 3. Bitget has completed its phased service restoration, while the Bitget Alliance Program continues to support clients' trading and capital management needs. We completed the planned restoration on October 2 and replenished the Protection Fund to more than $300 million on September 30. According to DefiLlama, assets tracked on the platform rebounded from approximately $5.647 billion on October 1 to $6.223 billion on October 11. This report also outlines VIP level protection, user rewards, and institutional fee incentives to help high-value clients plan their trading activities according to their account type. Assets to watch: BTC, ETH, SOL, SUI, PUMP, gold, JPM, BAC, and ASML. Key areas of focus this week: The October 14 U.S. CPI release; bank net interest income and credit costs; AI cash flow generation; and post-recovery trends in assets held on Bitget, settlement efficiency, and trading conditions. Market data are current through October 9 or the latest local trading day. Official announcements and promotion terms were reviewed through October 12.

Bitget•2026/10/13 07:46